Tonix Pharma's COVID-19 Vaccine Candidate Shows Encouraging Efficacy In Animal Studies

Tonix Pharmaceuticals Holding Corp TNXP jumps in premarket trading after announcing positive preliminary results following vaccination of non-human primates with TNX-1800, its COVID-19 vaccine candidate.

  • TNX-1800 is a modified horsepox virus encoding CoV-2 spike protein.
  • Immunogenicity and protective efficacy of single-dose TNX-1800 were assessed at two dose levels (n=4 per group).
  • On Day 41, after the vaccination, animals were challenged with live SARS-CoV-2. Protection was assessed at day 47, six days after the challenge.
  • All eight animals vaccinated with TNX-1800 had undetectable SARS-CoV-2 in their upper and lower airways six days after challenge with SARS-CoV-2.
  • Last year, the company reported that the vaccination was associated with neutralizing antibodies.
  • All eight of the animals vaccinated manifested a skin reaction to the vaccination, a validated biomarker of functional T cell immunity.
  • The current data shows that on day 14, after a single vaccination, all eight of the TNX-1800 vaccinated animals made anti-CoV-2 neutralizing antibodies against none in the control arm (TNX-801, horsepox virus, live vaccine) and placebo group.
  • The level of neutralizing anti-CoV-2 antibody production was similar between the low and high doses TNX-1800 groups.
  • TNX-1800 and TNX-801 were well tolerated at both doses.
  • These results support the expectation that TNX-1800 at the low dose of 1 x 106 PFU is an appropriate dose for a one-shot vaccine in humans and indicate that 100 doses per vial are the target format for commercialization.
  • Phase 1 human study is expected to start in the second half of 2021.
  • Price Action: TNXP shares were trading at 8.7% higher at $1.38 in premarket on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareSmall CapFDAGeneralCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!